IMARC Group has recently released a new research study titled “South Korea Biobanking Market Size, Share, Trends and Forecast by Specimen Type, Biobank Type, Application, End User, and Region, 2025-2033”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

South Korea Biobanking Market Overview

The South Korea biobanking market size was USD 1,225.45 Million in 2024. The market is projected to reach USD 1,930.60 Million by 2033, growing at a CAGR of 5.18% during the forecast period 2025-2033. This growth is primarily driven by government-led development of standardized biobank networks, capacity expansion, and rising demand from precision medicine and life-science R&D sectors. Technological advancements in automation, informatics, and data integration are further enhancing the market.

Study Assumption Years

  • Base Year: 2024
  • Historical Year/Period: 2019-2024
  • Forecast Year/Period: 2025-2033

South Korea Biobanking Market Key Takeaways

  • Current Market Size: USD 1,225.45 Million in 2024
  • CAGR: 5.18% (2025-2033)
  • Forecast Period: 2025-2033
  • South Korea has heavily invested in nationwide biobanking networks linked to academic hospitals, research institutes, and public health agencies.
  • Government policies mandate standardized bio-specimen collection, consent protocols, and data interoperability.
  • Technological integration includes automation, digital tracking, and AI-driven research platforms.
  • Ongoing projects like the ISA Deep-Sea Biobank initiative and CHA Bio Group’s Cell Gene Biobank-based Open Innovation Center will boost infrastructure.
  • Sector benefits from public funding, quality control, professional training, and ethical governance.

Sample Request Link: https://www.imarcgroup.com/south-korea-biobanking-market/requestsample

Market Growth Factors

The South Korea biobanking market is propelled by government-led initiatives focused on establishing standardized biobank networks with robust infrastructure across academic hospitals, research institutes, and public health agencies. These networks maintain diverse biological samples and genomic data that support translation research, precision medicine, and drug discovery efforts. Mandates on biobank quality and data interoperability ensure consistent and reliable biospecimen storage, driving investor and stakeholder confidence.

Technological advancements are a critical driver of growth. Automated cold storage with remote monitoring, barcode and RFID integration with laboratory information systems, and advanced informatics platforms that connect biospecimen data with genomic and clinical information enable AI-powered research applications. These innovative technologies enhance sample integrity and streamline research processes, attracting multinational clinical trials and biotech investments.

Public funding and strategic industry collaborations further catalyze market expansion. For example, the ISA Deep-Sea Biobank initiative signed in 2025, and CHA Bio Group’s Open Innovation Center scheduled for completion in 2025 demonstrate strong institutional commitment. These projects boost biobanking capacity and capabilities, from stem cell repositories to cGMP manufacturing, positioning South Korea as a key player in marine biotechnology, biodiversity conservation, and cell gene research.

Market Segmentation

  • Specimen Type:
  • Blood Products
  • Solid Tissue
  • Cell Lines
  • Nucleic Acid
  • Others
  • Biobank Type:
  • Population-based Biobanks
  • Disease-oriented Biobanks
  • Application:
  • Therapeutics
  • Research
  • End User:
  • Academic Institutions
  • Pharma and Biotech Companies

Ask For an Analyst- https://www.imarcgroup.com/request?type=report&id=39407&flag=C

Regional Insights

The report covers major regional markets within South Korea, including:

  • Seoul Capital Area
  • Yeongnam (Southeastern Region)
  • Honam (Southwestern Region)
  • Hoseo (Central Region)
  • Others

Seoul Capital Area stands as the dominant region, leveraging extensive biobanking infrastructure and research networks. The coordinated investments in infrastructure, professional training, and ethical governance ensure reliable, high-quality sample access, supporting both local and international stakeholders.

Recent Developments & News

  • On 5 January 2023, Seoul Clinical Laboratories (SCL) Biobank became the first in the Asia-Pacific region to receive ISO 20387:2018 accreditation from the American Association for Laboratory Accreditation (A2LA), confirming operational competence and adherence to international biological material handling standards.
  • On 26 March 2025, DKSH signed an agreement to acquire Seoul-based Molecular Diagnostics Korea Inc. (MDxK), which employs 25 staff and generates annual net sales of approximately USD 11 Million. This acquisition strengthens DKSH’s biobanking and scientific solutions portfolio in South Korea.

Key Players

  • Seoul Clinical Laboratories (SCL) Biobank
  • DKSH
  • Molecular Diagnostics Korea Inc. (MDxK)
  • CHA Bio Group
  • CIC

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302